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Abstract The International Society
for Strategic Studies in Radiology
(IS3R) brings together thought leaders
from academia and industry from
around the world to share ideas, points
of view and new knowledge. This
article summarizes the main concepts
presented at the 2007 IS3R sympo-
sium, providing a window onto trends
shaping the future of radiology. Topics
addressed include new opportunities
and challenges in the field of
interventional radiology; emerging
techniques for evaluating and
improving quality and safety in
radiology; and factors impeding
progress in molecular imaging and
nanotechnology and possible ways to
overcome them. Regulatory hurdles to
technical innovation and drug
development are also discussed more
broadly, along with proposals for
addressing regulators’ concerns
and streamlining the regulatory
process.
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Introduction
The modern transformation of radiology into an essential
guiding hand of medical practice began with the invention
of computed tomography imaging in the early 1970s and
continues today with novel applications based on molec-
ular methods and nanotechnology. The topical agenda of
the 7th Biannual Symposium of the International Society
for Strategic Studies in Radiology (IS3R), “Advancing
Radiology through Informed Leadership,” was chosen by
Program Committee Chairman Maximilian Reiser to
promote exploration and discussion of radiology’s con-
tinuing transformation, its implications for the care of
patients, and, more broadly, its impact on the health-care
systems of the world.
Major themes of the Symposium included the increasing
role of image-guided therapeutic interventions, the central
role of quality and safety, and the emergence of molecular
imaging and nanotechnology. Regulatory hurdles for tech-
nical innovation were addressed for both drugs and devices.
The IS3R brings together thought leaders from academia
and industry from around the world to share ideas, points of
view, and new knowledge. The following summary reflects
the contributions of these diverse voices and provides a
unique window for looking at important trends that are
shaping the future of radiology.
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Interventional radiology: new fields and challenges
The technology for minimally invasive, image-guided
interventions is advancing rapidly, aided by the convergence
of innovations from numerous scientific and medical
disciplines. As a result, a host of new options for the
minimally invasive diagnosis and treatment of disease are
broadening the horizons of interventional radiology (IR).
Fusion of images from different radiological techniques
is allowing more accurate and targeted intraoperative
navigation. For example, preoperative 3D CT angiography
is being successfully co-registered with intraoperative 2D
angiography to provide better depth perception and
navigation during angiographic liver interventions, with
motion correction for breathing [1]. Anatomical imaging is
also being combined with functional or molecular imaging.
Thus, the use of ultrasound to identify suspicious nodules
may be accompanied by the use of a gamma probe to
determine whether the nodules display functional activity
indicative of cancer [2]. In patients suspected to have
prostate cancer, targeted biopsies guided by the fusion of
ultrasound with MRI and MR spectroscopy are allowing
better cancer detection [3].
“Smart” devices are also improving navigation during
image-guided interventions. For example, the insertion of
miniature “smart” electromagnetic sensors into interven-
tional tools such as guide wires or needles allows their
progress through the body to be followed on a GPS-like
tracking system [4]. In this approach, the magnetic space of
the patient is co-registered with preoperative 3D imaging
data, essentially creating a road map for the intervention.
Not only does this lessen the need for intraoperative
imaging (which may involve exposure to ionizing radiation
and/or contrast media), it also opens up more possibilities
for bringing information from sophisticated preoperative
imaging techniques—such as PET or MRI—directly into
the interventional process [4].
Relatively inexpensive robotic instruments for needle
placement are now available. CT-integrated robots place
needles more accurately and consistently than humans, and
with the use of treatment planning software, they can
identify and access the most direct routes to their targets.
Although their cost-effectiveness has not yet been proven
in large-scale studies, they work rapidly and also reduce
interventional radiologists’ exposure to radiation [5].
Further tailoring of interventions is becoming possible
through the advent of “smart” drugs that are designed to
complement interventional techniques [6]. One example is
Thermodox™, which consists of thermosensitive liposo-
mal capsules that contain the chemotherapeutic agent
doxorubicin. The capsules release the doxorubicin only
under the high temperatures induced by thermal ablation.
When the capsules are injected into the tumor vasculature
at the time of radiofrequency ablation, the doxorubicin
takes effect throughout the tumor, including at the edges,
where radiofrequency ablation alone tends to be ineffective.
Because the doxorubicin is released only in the heated
area, its toxic side effects are limited. Another concept
consists of combining the application of thermosensitive
liposomal capsules with regional hyperthermia induced
by noninvasive, image-guided focused ultrasound [7].
With advances in nanotechnology, the potential for the
development of “smart” drugs appears limitless. For
instance, targeting antibodies or ligands could be attached
to drug-carrying capsules made with bound metal (to allow
imaging). Not only the ligands, but the agents inside the
capsules could be varied to target specific disease
characteristics. In a new paradigm of “molecular IR,”
molecular imaging-guided interventions could be used to
determine the molecular characteristics of a disease and to
subsequently deliver the appropriate targeted therapy [7].
Emerging cellular therapies could also play a role in IR.
Preliminary research suggests that the insertion of autol-
ogous bone marrow cells after myocardial infarction can
improve left ventricular function and myocardial viability
[8]. Various imaging techniques, including MRI, PET, and
SPECT, have been used to assess the functional effects of
cell therapy, and methods for tracking and labeling cells
with radionuclides and superparamagnetic agents are being
developed [9]. Although extensive clinical trials are still
needed, cellular therapy could potentially become an
important alternative to heart transplantation for the vast
numbers of patients suffering from severe heart disease
[10].
MR-guided focused ultrasound (MRgFUS) is another
novel interventional technique that could have applications
in a multitude of patients. In this procedure, hundreds of
ultrasound beams are directed at a focal point, where they
cause intensive local heating and tissue destruction. The
entire procedure, which is performed on an outpatient
basis, takes place inside the bore of the MRI magnet. MR
imaging is used to guide the beam, avoiding critical
structures such as nerves, scar tissue, surgical clips, and
bowels, and MR thermal mapping is used to monitor the
temperature rise (through a phase shift) and tissue
destruction [11]. MRgFUS is gaining acceptance as a
non-invasive treatment for uterine fibroids [12]. In a study
conducted in the UK, 80/100 patients treated with
MRgFUS for uterine fibroids had significantly less severe
symptoms 6 months after treatment [13]. Data suggest that
MRgFUS may have more long-lasting effects in the
treatment of uterine fibroids than the more invasive
alternative of myomectomy. MRgFUS has also been used
for the palliative treatment of bone metastases. Destruction
of periosteal nerves has been suggested as a possible
explanation for the analgesic effect, which cannot be
explained simply by the avid absorption of ultrasound
waves by bone. Although the inability of ultrasound waves
to pass beyond bones limits the areas that can be directly
accessed by the technique, MRgFUS is now being
evaluated for the treatment of intracranial tumors. Even
though 90% of the energy is reflected back by the
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calvarium, enough power remains to thermally ablate a
glioblastoma multiforme or liquefy a clot in acute stroke.
(The reflected energy is absorbed by a water bag.)
Moreover, results in the treatment of breast cancer as
well as soft-tissue metastases using MRgFUS have been
reported [14]. Radiologists have an essential role to play in
the development and application of MRgFUS, as it requires
substantial skill in the use of imaging to guide the
ultrasound beam.
The developments described above suggest great potential
for the growth of IR. However, despite a history of
introducing innovative and widely applicable techniques,
the field of IR has grown at a very slow rate, such that in 2002
there were only around 200 IR training positions in the
United States (as compared to around 2,300 in cardiology the
year before) [15]. To some leaders in the field, these numbers
suggest that the very survival of IR is at risk [16].
Repeatedly, techniques that have started out in IR have
ended up being adopted by organ-based specialties, and the
referrals to IR for these procedures have dropped off. For
example, by 2003, cardiologists in the US had caught up
with radiologists in the performance of peripheral vascular
stent procedures, and now the majority of such procedures
are performed by cardiologists [17]. With their direct
access to patients, their comparatively large numbers of
personnel, and their greater financial resources and
research activity, organ-based specialties have tremendous
advantages over IR in the competition for patients [18].
To sustain and enhance the relevance of IR, adjustments
to the standard IR training may be needed. Arguably, more
of the training could be focused on IR procedures and
equipment and less on diagnostic imaging, while still
providing the core skills necessary to achieve board
certification in radiology. Clinical skills should be
emphasized. Efforts should also be made to increase
recruitment into IR training programs, perhaps by looking
for candidates outside the field of radiology, in specialties that
attract more physicians who seek patient contact [19]. The
move in Europe to a 3-year core training with 2 years devoted
to sub-specialty training should help in this regard [20].
The relationship of IR to radiology may need to be
reconsidered. Should IR be separated from radiology and
become an independent clinical specialty? Should it remain
within radiology? Or should it be organized into partner-
ships with separate organ-based specialties? Each scenario
has advantages and disadvantages [21]. One advantage of
remaining within radiology is the access this affords to
advanced imaging equipment. However, if IR is to stay
within radiology, the differences between the work of
interventional radiologists and that of diagnostic radiologists
must be addressed. For example, since the former cannot bill
as many procedures as the latter, they should perhaps have a
separate accounting system. More hospital and departmental
resources should be devoted to marketing and community
outreach for IR. In addition, regardless of which organiza-
tional approach is pursued, interventional radiologists should
seek to obtain the status of true clinicians, with admitting
privileges and the administrative support and infrastructure
that will allow them to take more direct responsibility for
patient care.
Interdisciplinary collaboration and involvement in
research are also essential to enhance the growth of IR.
At present, IR lags far behind organ-based specialties in the
publication of original research. Many promising new
interventional techniques (including most of those de-
scribed above) have yet to be validated through extensive
clinical trials. More studies are needed to demonstrate their
benefits to patient outcomes [22] as well as to workflow.
With the continual advancement of technology, there are
also endless possibilities for creating new interventional
approaches. To enhance their contributions to research,
interventional radiologists should build strong collaborative
ties with physicians in other specialties as well as with the
radiochemists, physicists, computer scientists, engineers, and
basic scientists whose knowledge is essential for developing
new minimally invasive techniques.
Regardless of whether they continue to be applied under
the rubric of IR, the skills of interventional radiologists are
going to be increasingly in demand [23]. Furthermore, the
interventional radiologist who can deliver a comprehensive
range of emergency procedures will continue to be held in
high regard by professional colleagues.
Quality and safety
Rising health-care costs in the developed world have led to
increased scrutiny of the quality of care being purchased.
Four broad components of quality health care are now
widely recognized: appropriateness of care (as opposed to
overuse, underuse, or misuse of procedures); coordinated
care that links providers and information; safe, error-free
care; and patient-centered, timely care [24]. The methods
for evaluating these aspects of quality, however, are still
being developed and debated.
One common way of gauging quality has been to
compare usage of medical procedures across geographic
regions, institutions, and individual providers. For years,
wide variations in usage have been acknowledged to exist
in the US [25]. However, solutions to this problem have
been slow in coming. As recently as 2003, McGlynn et al.
found that on average, Americans received only about half
of recommended medical care (as defined by a panel of
physicians working on the study) [26]. Underuse of
medical processes was a much greater problem than
overuse, with 46.3% of study participants not receiving
recommended care and 11.3% receiving superfluous and
potentially harmful care.
Within radiology, it appears that the opposite may be
true. A study of the health-care provided to employees of
General Electric suggested that approximately half ($60
million-worth) of the radiological tests ordered were
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unnecessary [27]. Nevertheless, when used appropriately
radiological services can make health care better, quicker,
and cheaper, most often by diminishing diagnostic
uncertainty and obviating the need for additional (and
more invasive) procedures. More studies are needed to
demonstrate that radiology can improve outcomes and
reduce costs at every level, from the clinician, to the
department, the hospital, the insurer, the community, and
the nation [28, 29].
Refinements in the criteria for test usage and reporting
can lead to considerable increases in cost-effectiveness. For
example, a study in the UK found that the incremental cost
of using breast MRI would be £28,284 per cancer detected
[30] if it were applied in all patients who underwent
mammography, but only £11,731 if it were applied in place
of mammography for patients with BRCA1 and £15,302 if
it were applied in addition to mammography in patients
with BRCA2 [30]. Partly as a result of such findings, the
use of MRI in patients at high risk for breast cancer is now
being funded by the National Health Service (NHS) [31].
Another study found that by not reporting lesions smaller
than 6 mm seen on CT colonography, radiologists could
substantially reduce costs and complications while producing
only a trivial decrease in cancer detection [32].
To help develop imaging recommendations, more
studies are needed to determine whether imaging tests are
likely to improve clinical decision-making and outcomes.
Modeling can be used for this purpose. To yield results that
are applicable to a broad spectrum of clinical settings, more
meta-analyses of small studies, as well as more large multi-
center studies should be done. Aids for designing and
implementing clinical trials of imaging are readily available.
For example, the Web site of the American College of
Radiology Imaging Network provides access to standard
enrollment form templates and sample protocols [33].
Decisions about cost-effective radiological test usage
may be complicated by concerns about exposure to
ionizing radiation. Increasingly, patients are becoming
aware of the risks of radiation exposure. In the late 1990s, the
European Community issued Directive 97/43/EURATOM
outlining the need for justification, optimization, and
auditing of the use of ionizing radiation in health care.
Over the past 5 years, the European Commission issued
European Guidelines for Multislice Computed Tomography
(an update of an earlier set of guidelines for the use of CT)
[34] and launched the project “Safety and Efficacy of
Computed Tomography: A Broad Perspective.” The latter
project brings together radiologists and physicists from
leading European academic institutions to study CT
justification and radiation dose optimization and measure-
ment and to design practical tools for improving practice
(e.g., clinical decision trees and optimized CT techniques).
The project has resulted in published papers, conference
presentations, and a report to the Commission. However,
dissemination of the information has been incomplete.
Research is being outpaced by advances in imaging
technology. Furthermore, as CT is now widely available,
relatively affordable, and quick, guidelines for limiting its
use are being ignored to meet the demand for imaging, and it
appears that many, perhaps even most, CT examinations
performed in Europe are being requested in advance of
patients’ needs [35].
Increasing the availability of both ultrasound and MRI
should reduce reliance upon techniques involving X-rays,
particularly for young patients [36]. To address the problem
of radiation exposure more effectively, the government
must continue to support research and not only pass, but
also enforce laws through auditing. In addition, researchers
must work closely with industry to ensure that quality and
safety measures are incorporated into technology develop-
ment, and leaders in government, health care and industry
must prioritize quality and safety above (real or imagined)
productivity.
Various approaches are being pursued for improving—
and not just assessing—the quality and appropriateness of
health care. For patients on Medicare in the US, efficiency
measures have been proposed for the use of certain
radiological examinations, including MRI of the lumbar
spine and mammography. Recall rates after mammograms
are being evaluated to determine whether mammograms
are being performed in the appropriate patients [37].
Meanwhile, private insurers have begun to scrutinize
utilization rates per thousand patients. Ultimately, to
bring about large-scale changes in practice, information
on performance at all levels will need to be made routinely
available—a process that will require substantial changes
in health information systems, including automated entry
of essential data for clinical decision-making [24].
Health-care accreditation systems are now in use in the
US, Finland, and Australia. In 2006, the Royal College of
Radiologists (RCR) and the Society and College of
Radiographers began to develop the Radiology Accredita-
tion Project (RAP) to assess radiological services in the UK
[38]. At present, the RAP is still in the pilot stage and is
voluntary. Accreditation requires demonstration of appro-
priate protocols for monitoring and assuring the quality of
service relative to published standards for safety, patient
experience, clinical performance, and utilization of re-
sources and workforce. It also requires the development of
a quality improvement plan with achievable goals. Both
self-assessment and assessment by independent auditors
are performed.
The RCR is also working to establish a system for re-
licensing and re-certification of radiologists in the UK,
with the goal of identifying poorly performing ones. It is
known that the performance of approximately 2% of
radiologists in the UK falls 2 standard deviations below the
mean, yet only 0.5–1% of radiologists are referred for
evaluation by the National Clinical Assessment Service
[39]. Measuring the overall performance of individual
radiologists can be tricky. Theoretical knowledge and, to
some extent, practical skills can be assessed by examinations
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or more complex tests. However, assessment of profession-
alism and behavior has generally relied on informal
feedback, which is often considered unreliable and ignored.
In a survey that asked RCR members and fellows to choose
the best methods for identifying poorly performing radi-
ologists, third place went to peer review of cases, and second
place went jointly to attendance at discrepancy/error/
complications meetings and on-line assessments linked
with educational programs. First place went to a less
conventional approach:multiple-source feedback, consisting
of a confidential questionnaire for peers and patients, ranking
of behavior, skills and knowledge, and computerized com-
parison of the radiologist’s scores with those of other
radiologists and doctors, ideally both nationally and locally.
Rather than the assignment of pass or fail marks, the proposed
multi-source feedback approach requires further evaluation of
any radiologists who receive consistently low scores.
Although much emphasis is now being placed on
increasing efficiency, it is important to keep the focus of
attention on the patient. Business objectives are best met by
meeting patient care objectives. For example, the business
objective of an inpatient unit is to reduce the length of the
average patient stay in the hospital; for radiology, this
means minimizing the turnaround time from study request
to study completion, which both shortens the patient’s stay
and improves the patient’s care [40]. The use of flow charts
in work process analyses can help identify ways to reduce
waste and the potential for error. Some of the solutions may
be non-intuitive. For example, net savings may result from
hiring an extra full-time technician to keep an expensive
piece of equipment (e.g., an MRI machine) in operation
during examination preparation times and the primary
technician’s lunch hour and coffee breaks. Conversely, for
equipment that is less expensive to purchase and operate, it
may be more cost-effective to buy many units, so that they
can readily be used whenever needed, even if they are not
constantly in use. Improving productivity and care requires
establishing the right balance between equipment and staff
and providing the necessary training for staff to make
optimal use of equipment [41].
At present, the error rate in the US health-care industry
far exceeds those in the airline, telecommunications, and
computer industries. Teamwork and communication are
essential for improving this state of affairs. Traditionally,
the culture in medicine has encouraged physician autonomy
over teamwork. However, physicians and staff with average
skills but an exceptionally well-designed work process will
outperform those with better skills but a less coordinated
work process [42]. Approaches used to encourage commu-
nication in the airline industry, such as anonymous reporting
of errors and elimination of penalties for errors, have been
applied in health-care organizations and have been found to
increase the rate of error reporting, stimulate discussions to
improve work processes, and ultimately decrease the
incidence of errors [43]. Multidisciplinary team meetings
allow radiologists to make recommendations for the
clinically relevant use of imaging and deliver clinically
relevant interpretations.
Information technology, such as decision support for
order entry and computer-aided diagnosis algorithms, can
also help reduce errors and improve quality. Furthermore,
teleradiology is increasingly being used around the world
to augment local radiological services [44, 45]. In the US,
the most common use of teleradiology has been to allow
radiologists to interpret images from home, but approxi-
mately 50% of radiological practices are now using outside
service providers for interpretations on nights and weekends.
In parts of Europe and Asia, teleradiology is being used
across borders either to serve areas with a shortage of
radiologists or to allow secondary consultations with
specialists, or both [46]. The use of Indian teleradiology
services in Singapore has improved care by reducing patient
wait times and allowingmore rapid clinical decision-making;
it has also forced radiologists in Singapore to work faster in
order to prove their worth.
Limited communication may be the most significant
drawback of teleradiology, as direct access to complete
clinical information, including prior imaging studies, is
rarely available, and teleradiology reports are usually
submitted by e-mail or fax, without direct contact between
the radiologist and the referring physician. Auditing is
needed to ensure that teleradiologists meet the same
certification and training requirements as local radiologists
and that adequate clinical and technical standards are being
maintained. Although a study comparing interpretations
made byNHS radiologists with thosemade by teleradiologists
at an independent service provider found few discrepancies,
most of the cases examined were of low complexity [47]. The
RCR, the American College of Radiology, and the European
Society of Radiology (in conjunction with the European
Union of Medical Specialists) have all issued fairly similar
guidelines for quality assurance in teleradiology [48].
Molecular imaging and nanotechnology
The potential of molecular imaging to revolutionize health
care is often spoken of in rhapsodic terms. Yet the practice
of molecular imaging (MI) within radiology continues to
be confined to a relatively small number of institutions and
settings. Though MI already has clear applications in
neurodegenerative conditions, cardiovascular disease, in-
flammation [49], and above all, cancer, a number of obstacles
are impeding progress toward its broad clinical implementa-
tion—some of them avoidable, others less so.
It is hoped that “system characterization” by imaging
probes will ultimately allow molecular knowledge devel-
oped in the laboratory to be translated to clinical disease
management [50]. In combination with in-vitro molecular
markers, MI (performed mainly with multimodality
techniques, such as PET/CT and PET/MR) [51] should
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facilitate earlier, even preclinical disease detection and
characterization, prediction of prognosis, targeted treatment,
and precise treatment follow-up, allowing “personalized
medicine” that is tailored closely to the individual patient.
However, both physical and technical factorsmake achieving
this vision a highly complex and challenging endeavor.
The body is equipped with many barriers to molecular
transport—such as nuclear, cellular, and vessel walls,
and the blood brain barrier. The development of probes
suitable for use in humans is limited by pharmacoki-
netics, biocompatibility, and toxicity concerns, and
imaging speed and resolution. Contrast agents and
radiopharmaceuticals must have sufficient half lives
and must aggregate in sufficient concentrations to allow
effective imaging once they have reached their target
destinations. In addition, for any one disease, a limited
number of overexpressed molecular markers will exist
for targeting [52].
Molecular interactions and disease processes are com-
plex, and knowledge of them remains limited. AlthoughMI
with PET has been used successfully to explore how new
drugs interact with targeted systems and to narrow the
feasible dose ranges, PET imaging results can also be
misleading. For example, during its development, the anti-
psychotic drug aripiprazole had no clinical effectiveness at
the feasible dose range identified by PET, but in practice,
the drug was found to be effective and safe at substantially
higher doses. While MI can show on-target biological
activity and provide essential information about the
biodistribution of drugs, both more knowledge and more
probes are needed to increase the reliability of MI for
assessing drug effects. In certain instances, it may soon be
possible for MI to play a role in disease stratification,
patient selection for therapeutic agents, and dose selection
[52], but MI is unlikely to replace clinical endpoints in drug
development for a long time to come.
Nanotechnology offers enormous versatility in the
development of MI probes. The advent of particle repli-
cation in non-wetting templates (PRINT) technology has
made it possible to mold nanoparticles small enough to
cross the blood-brain barrier [53]. Not only the size, but
also the ability of nanoparticles to deform can be tailored to
their purpose, increasing or limiting their uptake. In
addition, nanoparticles can be filled with cargoes (e.g.,
antibodies) and can have entities (e.g., targeting ligands)
attached to their surfaces [54]. Applications for which
nanoparticle-based contrast agents are expected to be
introduced into clinical practice within the next 10 years
include imaging of metastatic lymph nodes, vulnerable
atherosclerotic plaque imaging, macrophage imaging for
inflammatory and degenerative diseases (e.g., multiple
sclerosis, polyarthritis and osteomyelitis), and imaging of
amyloid plaques in Alzheimer’s disease.
Many more probes might now be on the horizon were it
not for the vast amounts of time and money required to
overcome regulatory hurdles. In the US, this problem has
been exacerbated by misconceptions about regulatory
requirements. Many applications for pharmacology/
toxicology studies have been submitted with much more
background data than necessary [55]. In 2006, the FDA
issued guidelines for exploratory investigational new drug
(IND) studies (e.g., screening studies or microdose studies)
that are conducted early in phase 1 of the trial process,
involve very limited human exposure for a short time
period (e.g., 7 days), and have no diagnostic intent [56].
The guidelines explain that because exploratory IND
studies present fewer potential risks than do traditional
phase 1 studies that look for dose-limiting toxicities, they can
be initiated with less, or different, preclinical support than is
required for traditional IND studies [56]. Exploratory
IND studies allow a large number of agents to be tested
rapidly in order to distinguish the promising from the
not-so-promising, decreasing the likelihood of failure in
later clinical trials.
While exploratory IND studies are extremely useful,
further simplification of regulatory processes is necessary,
as is the creation of a viable business model for probe
development. The development of MI probes that deliver
drugs could allow much more targeted treatments of
disease with less morbidity. However, trials of such probes
are especially complex and doubly risky for the sponsors,
since either the imaging probe or the drug may fail.
Collaboration between academia and industry in probe
development has been hampered by concerns about
intellectual property rights. Furthermore, lack of reimburse-
ment discourages experimental use of molecular imaging in
hospital settings, particularly since the required multimod-
ality imaging techniques are expensive [57]. Despite these
obstacles, collaboration between industry and academia is
possible in MI research and probably essential for academic
institutions. In a recent survey of academic radiology
departments with MI programs in the US, only 16.1% had
no alliances with industry [58].
Another barrier to progress in the clinical implementa-
tion of MI is the need for expertise from multiple
disciplines. Radiologists tend to have little understanding
of molecular biology, and few have any familiarity with
molecular imaging, since it is not included in standard
clinical training. To encourage more radiologists (and other
physicians) to become involved in the field, MI rotations
should be created, and more MI fellowships should be
offered. In the survey referenced above, respondents
identified staff training and recruitment as the most
essential elements for success [58]. In light of the extensive
training in both basic science and multimodality imaging
required for the field, the creation of a new specialty of MI
may be warranted, with the possibility of dual boarding in
diagnostic radiology and MI, or nuclear medicine and MI.
Because MI involves not only multiple disciplines but
multiple kinds of technology, its success will require major
investments in human resources and infrastructure. It will
also require significant changes in organizational structures
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and the setting aside of turf battles. Conceivably, molecular
biology, pathology, and imaging could be combined under
one umbrella, perhaps that of “biomedical imaging” or
“imaging science” [60]. Alternatively (or concomitantly),
the typical “Department of Diagnostic Radiology” could be
replaced by a “Department of Diagnostics,” combining
pathology with radiology and MI, and using pathological
analysis of genes and proteins to identify targets and create
agents for MI in individual patients. Regardless of the
specific restructuring plan chosen, broad clinical imple-
mentation of MI will depend on collaboration, co-training,
and co-ownership.
Regulatory hurdles
Approval hurdles for pharmaceutical media
and technology
Regulatory requirements pose daunting barriers to the
introduction of radiological innovations. For example, a
pharmaceutical company is likely to spend over $300
million to bring a new contrast agent to market, in a process
that typically takes about 9 years. And that is only the
beginning. For each new indication, about $15 million
more in funds is required and around 5 more years,
although most radiologists ignore the package insert and
engage in “off label” use. While the process is somewhat
less onerous in Europe than in the US, regulatory hurdles
appear to be increasing around the world.
The need to meet different regulatory requirements in
different areas of the world adds to the complexity and
costs of the process. Currently, regulations differ in the EU
and the US, China and Japan, with the regulatory policies
of the latter two countries being closer to those of the US.
In both the EU and the US, regulators look for accuracy
(e.g., as measured by sensitivity and specificity), reliability,
clinical value, and a favorable risk/benefit ratio. However,
far more contrast agents have been approved in Europe
than in the US to date. This may be partly because US
regulators seem to place a greater emphasis on the
demonstration of p-values showing statistically significant
increases in value over existing technology or agents,
whereas EU regulators are more content to see any
demonstration of utility, even if it is only for a secondary
aim [61]. Furthermore, in the US, the requirements are
often not aligned with the intended use of the agent or
device. For example, even if the manufacturer’s goal for a
contrast agent is to increase tumor visualization, the FDA
may demand that the manufacturer also demonstrate an
improvement in tumor diagnosis. Such a demand may
prevent a useful agent from coming to market, or may
require it to be tested (and approved) for a narrower cohort
and indication.
Advances in technology occur faster than does the
development of new contrast agents. Thus, delays in
the approval process for an agent can make the agent or the
application tested obsolete by the time it becomes
available. Moreover, partly because of the fast pace of
technological change, standardization of imaging protocols
in multi-center trials is difficult, as is comparison of the
results of multiple single-center studies.
In a phenomenon sometimes referred to as “regulatory
creep,” the FDA has repeatedly come back to manufac-
turers and pharmaceutical companies with requests for
more data, more details, and stricter adherence to protocols.
To prevent this, the FDA should be required to make
binding agreements about what is required at the beginning
of the regulatory process. Recently, the FDA began to call
for clinical trials to assess the use of a contrast agent on a
new imaging platform, even when the contrast agent has
already been approved. This shortens the effective lifetime
of the new device, reducing the incentive for the
manufacturer to invest in the trial process.
In Japan, regulatory requirements have also multiplied
recently. The average approval time for a new medical
device in Japan in 2004 was 1,083 days, compared to 356
in the US [62]. The number of new device applications
submitted by US companies for review by Japanese
regulators fell from 132 in 2003 to only 8 in 2005—a
decrease of 94%. Representatives of the US medical
technology industry cited “burdensome applications and an
unpredictable approval process” as reasons for the decline
[62].
In the US, it appears that increasing delays in the
approval process are partially due to a lack of trained
regulatory personnel, as well as regulators’ tendency to
become concerned by negative anecdotal studies. In Japan,
where the approval process is even more complex, the
number of experienced reviewers is even smaller, and there
is a large backlog of applications. It may seem curious that
regulations should be multiplying even during times of
reviewer staffing shortages. Some speculate that the
changes may be part of a deliberate effort on the part of
governments to reign in health-care spending by reducing
the approval of new medical devices and drugs. However,
such a practice may in fact lead to greater social and
economic costs overall. Increasing the duration and cost of
the regulatory process is only likely to increase the cost of a
medical device or agent once it comes to market.
Furthermore, improvements in technology ultimately
lower the cost of quality health care. For example, since
CT was first introduced, the number of CT slices per
second has increased—from 1 in 1995 to 387 in 2006;
meanwhile, the cost per slice has gone down, so that for
the same overall price, much more information is
acquired. While it is easy to add up medical expenses,
it is less easy to calculate the costs (not to mention the
ethical drawbacks) of not delivering efficient, high-
quality medical care.
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Proposals for improvements
To speed up the introduction of innovations into clinical
practice, regulatory processes should be harmonized
globally. Members of academia and industry should
encourage their governments to adopt the recommendations
of the Global Harmonization Task Force, a partnership
between regulatory authorities and regulated industry
representatives from the European Union, the US, Canada,
Australia, and Japan.
The development of new medical products could be
streamlined through increased collaboration between
industry and academia. For example, the pattern in
technology development has been to design a piece of
equipment and then search for ways to apply it clinically—
a rather inefficient process. More communication between
members of academia and industry could allow technology
to be developed in response to specific clinical needs [63].
Fellowships enabling representatives of academia to train
with industry (or vice versa) could lead to greater mutual
understanding of priorities and could help improve multi-
center clinical trials—say, by facilitating standardization of
technology and of institutional imaging protocols.
Efficiency in product development could also be
improved by considering the whole imaging system, rather
than working on different parts of it in isolation. Modern
imaging requires a series of steps, including data acquisi-
tion, data reconstruction, and processing, data analysis and
output, and data interpretation. Different disciplines are
involved in the design of the equipment used for the
separate steps, including engineering, physics, and com-
puter science. Greater communication among all disci-
plines involved is more likely to result in advances that
improve the effectiveness of the overall imaging system
[63].
Trial design and conduct could also be improved with
more collaboration among industry, academia, and govern-
ment agencies—e.g., through organizations such as the
American College of Radiology Imaging Network
(ACRIN) [64]. Curricula could be redesigned to mandate
training in basic and clinical research all along the
educational pathway, starting with medical school. In
addition, industry and academia could work together to
train radiologists in the use of new imaging technology and
applications even before they receive regulatory approval.
This could not only improve the performance of new
devices or techniques in clinical trials, but also could lead
to earlier, broader acceptance of the techniques and faster
progress toward reimbursement.
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